30,191 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Callan Family Office LLC

Key Points

• Callan Family Office LLC acquired a new position in Teva Pharmaceutical Industries, purchasing 30,191 shares valued at approximately $506,000 during the second quarter.
• Teva reported a quarterly earnings per share of $0.66, exceeding analyst expectations of $0.64, although its revenue fell short of estimates at $4.18 billion.
• UBS Group raised its price target on Teva shares from $23.00 to $26.00, maintaining a "buy" rating, while the consensus rating currently stands at "Buy" with a target price of $25.57.

Callan Family Office LLC bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 30,191 shares of the company's stock, valued at approximately $506,000.

A number of other large investors also recently modified their holdings of TEVA. Golden State Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at $39,000. New Age Alpha Advisors LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at $43,000. Sound Income Strategies LLC lifted its stake in Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock valued at $49,000 after acquiring an additional 2,824 shares in the last quarter. Banque Cantonale Vaudoise bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at $74,000. Finally, Brooklyn Investment Group lifted its stake in Teva Pharmaceutical Industries by 403.4% during the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after acquiring an additional 4,014 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 0.5%

Shares of TEVA opened at $20.13 on Wednesday. The business has a 50-day moving average of $18.69 and a 200 day moving average of $17.02. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm has a market cap of $23.08 billion, a P/E ratio of -125.78, a price-to-earnings-growth ratio of 1.10 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same quarter last year, the firm posted $0.61 EPS. The firm's revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.57.

Insider Activity

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.